Promis Neurosciences (NASDAQ:PMN) was downgraded by analysts at
Wall Stre
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Canadian Business Journal (Canada)]
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing